Status:

RECRUITING

Effects of Combined 40 Hz Audio-visual Stimulation and Cognitive Games on Alzheimer's Disease

Lead Sponsor:

Istanbul Medipol University Hospital

Collaborating Sponsors:

The Scientific and Technological Research Council of Turkey

Guven Health Group

Conditions:

Alzheimer's Disease

40 Hz Stimulation

Eligibility:

All Genders

60-86 years

Phase:

NA

Brief Summary

In addition to ongoing drug treatments for Alzheimer Disease (AD), protective approaches that can halt the progression of the disease are of particular importance. This project aims to develop a digit...

Detailed Description

This study aims to recruit early and middle-stage Alzheimer patients aged between 60 and 75, along with age and gender-matched healthy older adults. Two different Alzheimer groups will be created: one...

Eligibility Criteria

Inclusion

  • Inclusion and Exclusion Criteria for Alzheimer Patients:
  • Diagnosed with AD according to DSM-IV and NINCDS-ADRDA criteria,
  • Impaired activities of daily living,
  • Having a CDR score of 1-2 and an SMMT score of 15-26,
  • Stable use of psychoactive medications, including acetylcholinesterase inhibitors or other medications that enhance cognitive functions,
  • Individuals aged 60-86 with at least 5 years of education.

Exclusion

  • Having frontotemporal dementia, vascular dementia, Lewy body dementia or other types of dementia,
  • Parkinsonism, clinical depression, other mental disorders, epilepsy, drug addiction, alcohol addiction, and traumatic brain injury
  • Inclusion and Exclusion Criteria of Healthy Older Adults:
  • Inclusion criteria:
  • Between the ages of 60-86
  • Without any neurological abnormalities or general cognitive impairment (MMSE above 25),
  • Not diagnosed with a neurological and/or psychiatric disease,
  • Not using neurological and/or psychiatric medication
  • Exclusion criteria
  • Having clinical signs of cognitive impairment, such as mild cognitive impairment, Alzheimer disease, Parkinson disease, Lewy body dementia, frontotemporal dementia, etc.
  • Epilepsy, alcohol and/or drug addiction, use of medications that affect cognitive functions, and traumatic brain injury

Key Trial Info

Start Date :

October 1 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 30 2025

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT06595511

Start Date

October 1 2022

End Date

April 30 2025

Last Update

September 19 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Istanbul Medipol University

Istanbul, Beykoz, Turkey (Türkiye), 34810